Entasis Therapeutics Inc (ETTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
43
About the Report
About the Report
Summary
Entasis Therapeutics Inc (Entasis) is a drug development company that discovers and develops anti-infective therapies for drug-resistant bacterial infections. The company's pipeline products include ETX2514, ETX0282, ETX0914 and Zoliflodacin. Its ETX2514 is a potent inhibitor of class A, C, and D beta-lactamases intended to treat serious gram-negative infections. Entasis' ETX0914, is an oral antibiotic for the treatment of uncomplicated gonorrhoea. The company's pipeline products are used to treat multidrug-resistant gram-negative infections such as pseudomonas aeruginosa, acinetobacter baumanii, carbapenem-resistant enterobacteriaceae, and neisseria gonorrhoeae, among others. It also develops robust clinical and pre-clinical pipeline of medicines. Entasis is headquartered in Waltham, Massachusetts, the US.
Entasis Therapeutics Inc (ETTX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Entasis Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Entasis Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Entasis Therapeutics Raises Additional USD32 Million in Series B-1 Financing 12
Entasis Therapeutics Raises USD50 Million in Series B Financing 14
Entasis Therapeutics Raises USD40 Million in Series A Venture Financing 15
Partnerships 16
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 16
Licensing Agreements 17
Zai Lab Enters into Licensing Agreement with Entasis Therapeutics 17
Equity Offering 18
Entasis Therapeutics Prices IPO of Shares for USD75 Million 18
Entasis Therapeutics Spin Out from AstraZeneca 20
Entasis Therapeutics Inc-Key Competitors 21
Entasis Therapeutics Inc-Key Employees 22
Entasis Therapeutics Inc-Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Nov 14, 2018: Entasis Therapeutics reports third quarter 2018 financial results 24
Corporate Communications 26
May 01, 2018: Entasis Therapeutics Appoints David C. Hastings to Board of Directors 26
Apr 10, 2017: Entasis Appoints Mike Gutch as Chief Financial Officer and Chief Business Officer 27
Product News 28
06/30/2017: Entasis Publishes Data Highlighting the Potent and Differentiated Activity of ETX2514 Combinations against Drug Resistant Gram-negative Bacteria Including Acinetobacter and Pseudomonas 28
06/07/2017: Entasis Therapeutics Presents Data on ETX2514 at ASM Microbe 2017 29
06/06/2018: Entasis Therapeutics to Present Data on ETX0282 at ASM Microbe 2018 30
05/22/2017: Entasis Therapeutics to Present Data on ETX1317 at ASM Microbe 2017 31
05/22/2017: Entasis Therapeutics to Present Data on ETX2514 at ASM Microbe 2017 32
05/22/2017: Entasis Therapeutics to Present Data on ETX0282 at ASM Microbe 2017 33
Clinical Trials 34
Aug 14, 2018: Entasis Therapeutics announces positive topline results from phase 2 trial of ETX2514SUL in patients with complicated urinary tract infections including acute pyelonephritis 34
Jun 06, 2018: Entasis Therapeutics to Present Data on ETX2514 at ASM Microbe 2018 35
May 14, 2018: Entasis Therapeutics Initiates Clinical Studies of the Oral Extended-Spectrum Beta-Lactamase Inhibitor ETX0282 37
Oct 12, 2017: Entasis Therapeutics Receives Second CARB-X Award, Providing up to USD 10.1 Million for Development of Non-Beta-lactam PBP Inhibitor Program 38
Oct 09, 2017: Entasis Therapeutics Highlights Positive Phase 1 Data for ETX2514 at IDWeek 2017, Announces Plans to Advance Combination with sulbactam (ETX2514SUL) into Phase 2 Trials 39
Sep 28, 2017: Entasis Therapeutics to Present Phase 1 Data on ETX2514 at IDWeek 2017 40
Jun 07, 2017: Entasis Therapeutics Presents Data on Third Drug Candidate, ETX0282, an Orally Available, Extended-Spectrum eta-lactamase Inhibitor, at ASM Microbe 2017 41
Apr 21, 2017: Entasis Therapeutics to Present Data on ETX2514SUL at 27th European Congress of Clinical Microbiology and Infectious Diseases 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43
List of Figure
List of Figures
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Entasis Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Entasis Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Entasis Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Entasis Therapeutics Raises Additional USD32 Million in Series B-1 Financing 12
Entasis Therapeutics Raises USD50 Million in Series B Financing 14
Entasis Therapeutics Raises USD40 Million in Series A Venture Financing 15
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 16
Zai Lab Enters into Licensing Agreement with Entasis Therapeutics 17
Entasis Therapeutics Prices IPO of Shares for USD75 Million 18
Entasis Therapeutics Spin Out from AstraZeneca 20
Entasis Therapeutics Inc, Key Competitors 21
Entasis Therapeutics Inc, Key Employees 22
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.